Tiziana Life Sciences is hosting a virtual key opinion leader event to discuss intranasal administration of foralumab in multiple sclerosisMonday, March 14 at 11 a.m. ET, registration details below
NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) — Tiziana Life Sciences Plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel drug delivery routes, today announced that it will host a virtual Key Opinion Leader (KOL) webinar, “Foralumab Clinical Update in Multiple Sclerosis: A Landmark Study with Intranasal Immunotherapy” on Monday, March 14, 2022 at 11:00 a.m. EST .
This webinar will include presentations to discuss clinical data and the importance of intranasal immunotherapy with foralumab in neurodegenerative diseases. Professor Howard Weiner, MD, of Harvard Medical School, Professor Tanuja Chitnis, MD, of Massachusetts General Hospital, Professor Tarun Singhal, MD, of Brigham and Women’s Hospital, and Professor Lawrence Steinman, MD, of Stanford Medicine will discuss the current therapeutic landscape for inflammatory neurodegenerative diseases and the potential for new locally acting immunotherapies capable of crossing the blood-brain barrier, presenting a unique challenge for drug delivery to the central nervous system. As part of the discussion, KOLs will discuss clinical data related to intranasal foralumab in multiple sclerosis that Tiziana reported on March 10, 2022.
Tiziana is currently evaluating an innovative and proprietary formulation of foralumab, a fully human anti-CD3 monoclonal antibody for intranasal administration to treat secondary progressive multiple sclerosis (SPMS), and recently announced positive clinical data from a treated SPMS patient. for six months with Foralumab administered intranasally.
A live Q&A session will follow. To register for the event and pre-submit questions to management or KOLs, please clickhere.
Howard L. Weiner, MD, is the Robert L. Kroc Professor of Neurology at Harvard Medical School, director and founder of the Partners Multiple Sclerosis Center, and co-director of the Center for Neurologic Diseases at Brigham & Women’s Hospital. Dr. Weiner established the Partners Multiple Sclerosis Center at Brigham & Women’s Hospital in 2000, which combines clinical assessment, MRI imaging and immune monitoring and is the first integrated MS center that brings these disciplines to individual patient care with MS. Dr. Weiner pioneered the use of immunotherapy and the drug cyclophosphamide for the treatment of multiple sclerosis and studied immune abnormalities in the disease, including the role of the innate immune system and regulatory T cells. He also pioneered the use of the mucosal immune system for the treatment of autoimmune and other diseases, including ALS, Huntington’s disease and stroke. Based on his work, vaccines are being tested in multiple sclerosis, diabetes and, more recently, in Alzheimer’s disease. He is also developing new therapeutic options for neuromyelitis optica (NMO).
Dr. Weiner is the author of “Curing MS: How Science is Solving the Mystery of Multiple Sclerosis” which chronicles the history of MS, his more than 30 years in MS research and clinical treatment, and details his “21 point hypothesis” on the etiology and treatment of multiple sclerosis. In 2004, Harvard Medical School honored Dr. Weiner with the establishment of the Endowed Professorship of Neurology Professor Howard L. Weiner.
Tanuja Chitnis, MD, is the director of the Mass General Brigham Pediatric MS Center at Mass General Hospital for Children. She also sees adult MS patients at Brigham and Women’s Hospital. She completed her medical training at the University of Toronto Medical School, her neurology residency in Philadelphia, and a fellowship in multiple sclerosis and neuroimmunology at Harvard Medical School’s Brigham and Women’s Hospital. Dr. Chitnis has a long-standing interest in pediatric MS. She is president of the International Pediatric MS Workgroup and has written numerous publications and reviews related to multiple sclerosis. She is actively involved in several research projects to help better understand and treat MS in children.
Tarun Singhal, MD is Director of the PET Imaging in Neurological Diseases Program at the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital and Assistant Professor of Neurology at Harvard Medical School and Boston, MA. Dr. Singhal completed his medical studies at the All India Institute of Medical Sciences and completed a nuclear medicine residency in India before coming to the United States in 2006. He completed a postdoctoral fellowship at the Yale PET Center and the Kettering PET center, then in neurology and nuclear medicine. residency and fellowships at Harvard. He is board certified in Neurology and Nuclear Medicine and has been on the Harvard faculty since 2014. Dr. Singhal has led several molecular imaging projects in the field of neuroscience, including work on [C-11]Methionine PET in brain tumours, norepinephrine transporter imaging of the central nervous system and, more recently, PET imaging of neuroinflammation in multiple sclerosis and related disorders. Dr. Singhal maintains an active clinical practice seeing MS patients in addition to directing the PET imaging program in neurological diseases at Brigham and Women’s Hospital.
Lawrence Steinman, MD is a professor of neurology and neurological sciences, pediatrics and genetics. He was also chair of Stanford University’s Interdepartmental Immunology Program from 2003 to 2011.
Dr. Steinman’s research focuses on what causes relapses and remissions in multiple sclerosis (MS), the nature of molecules that curb brain inflammation, and the search for a tolerant vaccine for autoimmune diseases such as type 1 diabetes and neuromyelitis optica. . He developed two antigen-specific therapies, using DNA vaccines, for MS and type 1 diabetes. He was lead author of the seminal 1992 paper in Nature which reported the key role of a particular integrin in brain inflammation. This research led to the development of the drug Tysabri, which is used to treat patients with multiple sclerosis and Crohn’s disease.
About Tiziana Life Sciences, Ltd.
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. The novel nasal, oral and inhalation approaches of Tiziana being developed have the potential to improve efficacy as well as safety and tolerability compared to intravenous (IV) administration. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies nowadays. Tiziana’s technology for alternative immunotherapy pathways has been patented with several pending applications and is expected to enable broad pipeline applications.
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates and projections regarding its industry; his beliefs; and assumptions. Words such as “anticipates”, “expects”, “intends”, “plans”, “believes”, “seeks”, “estimates” and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company’s control, are difficult to predict and could cause actual results differ materially from those expressed or anticipated. in forward-looking statements. The Company cautions securityholders and potential securityholders not to place undue reliance on these forward-looking statements, which reflect the Company’s views only as of the date of this announcement. Forward-looking statements made in this announcement relate only to events as of the date the statements are made. The Company undertakes no obligation to publicly release revisions or updates to these forward-looking statements to reflect unforeseen events, circumstances or developments occurring after the date of this announcement, except as required by law or any applicable regulatory authority. ‘required.
Tel: (646) 970-4681
Tiziana Life Sciences Ltd
Hana Malik, Head of Business Development and Investor Relations
+44 (0) 207 495 2379